OABI logo

OMNIAB INC

OABINASDAQ
πŸ† #2552 by market capEarnings Mar 2 Β· PostUS Equity
β€”β€”
Quote unavailable
πŸ””
Track OABI
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$680M
Small Cap
πŸ“ˆRevenue Growth (YoY)
90.6%
High Growth
πŸ“ŠGross Margin
97.7%
High
πŸ’΅FCF Margin
32.7%
Strong
βš–οΈP/S Ratio
18.2x
Expensive
Otter Score
β€”
Insufficient data
No chart data available for OABI.

Trading Snapshot

Day Range
β€”
52-Week Range
$1.35 – $5.45
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
145.9M
Next Earnings
2027-03-02

Fundamentals Snapshot

Annual Revenue
$19M
Last Q Revenue
$4M
P/E Ratio
β€”
P/S Ratio
18.2x
EPS (TTM)
$-0.34
Dividend Yield
β€”
Dilution (1yr)
+21.9%
OABI logo

OMNIAB INC

OABI
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$19Mβ–Ό βˆ’29.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-18.2%β–Ό βˆ’118.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$72Mβ–Ό βˆ’4.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$37Mβ–Ό βˆ’10.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
127.8Mβ–² +21.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$5Mβ–² +$756K YoY
StockOtter Β· stockotter.space

About OMNIAB INC

OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.